Cor Therapeutics, Inc.

University of California

Millennium Pharmaceuticals Limited

Larry J Fretto

Lewis T Williams

David Lawrence Wolf

Jaime A Escobedo

Neill A Giese

James E Tomlinson

Vanitha Ramakrishnan

Maria Amelia Escobedo

Robert M Scarborough

Pamela B Conley

Hans-Michael Jantzen

Alan M Laibelman

Nathalie Lokker

The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

Inhibitory immunoglobulin polypeptides to human PDGF beta receptor

Platelet ADP receptor inhibitors

Defined constructs of modified human platelet-derived growth factor receptor polypeptides are provided. Extracellular region domain structures are identified and modifications and combinatorial rearrangements of the receptor segments are provided. Both cell bound and soluble forms of modified segments are made available, as are methods for assays using them, allowing for screening of ligand analogues.

Methods of using domains of extracellular region of human

This invention provides antibodies that bind to epitopes of human platelet-derived growth factor receptor (hPDGF-R) fragments, wherein the fragments comprise one or more platelet-derived growth factor (PDGF) ligand binding regions from extracellular domains D1, D2, and D3. Also provided are antibodies specific for domain D3, such as monoclonal antibodies directed to the intra-cysteine portion of domain D3.

Human platelet-derived growth factor receptor extracellular domain

Domains of extracellular region of human platelet derived growth factor

Methods and compositions are provided for treating several acute disease states associated with smooth muscle cell proliferation as well as the chronic process of atherogenesis utilizing oligopeptides corresponding to regions of the PDGF receptor protein. The oligopeptides can be used to block PDGF binding and activation for numerous applications, and can serve as immunogens to raise receptor-specific antibodies.

PDGF receptor blocking peptides

Growing community of inventors

Belmont, CA, United States of America

Larry J Fretto